CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When? An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Cardiac Shock Care Centers: JACC Review Topic of the Week Canadian SCAD Cohort Study: Shedding Light on SCAD From a United Front Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials

Editorial2019 Apr 22;12(8):731-733.

JOURNAL:JACC Cardiovasc Interv. Article Link

Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When?

Berry C, Collison D, Mangion K. Keywords: ST-segment elevation myocardial infarction; fractional flow reserve; multivessel disease; percutaneous coronary intervention; remodeling

LINK

Please click on "Article Link" to get further access to this Editorial.